Alpro Group, in collaboration with Boehringer Ingelheim, has introduced Jaga CarDia, a nationwide programme in Malaysia designed to tackle the rising incidence of heart and kidney diseases. This initiative, launched on 18 November, offers subsidised early detection screenings to help 5,000 Malaysians on long-term medication identify early signs of heart, kidney, and liver damage.
The Jaga CarDia programme provides essential blood tests covering over 70 health indicators at a subsidised rate of $21 (RM 100) for two people. This family-oriented approach encourages Malaysians to proactively manage their health. “Early detection is the foundation of better health outcomes,” said Dr Ng Ming Lee, Medical Director of Alpro Clinic. The initiative aims to shift focus from treatment to prevention, fostering long-term awareness about early detection as a defence against serious complications like heart failure and stroke.
Recent statistics from the Department of Statistics Malaysia highlight the urgency of this initiative. Ischaemic heart disease was the leading cause of death in 2022, accounting for 16.1% of medically certified deaths, with many victims under 60. Additionally, a study published in BMC Nephrology revealed that 15.5% of Malaysian adults suffer from chronic kidney disease, yet few are aware of their condition.
Boehringer Ingelheim’s General Manager, Cheong Yee Kok, emphasised the importance of early detection, stating, “Our collaboration with Alpro Group reflects our belief that early detection and continuous monitoring are just as vital as treatment itself.”
Jaga CarDia screenings are available at all Alpro Clinic outlets nationwide, offering personalised guidance from healthcare professionals. Eligible Malaysians are encouraged to register and schedule appointments to take preventive action before conditions become severe.
